EventsThe 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics
Published
This submission belongs to the session S4. New Small molecules as drug candidates of the event The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics
Published date
29 Oct, 2025
Academic Editor
author-avatarSerena Massari
Citation
Dau Ram, N. S. Hari Narayana Moorthy, Karthikeyan Chandrabose, Development of Kojic Acid–3-Hydroxyindolin-2-one Conjugates: Structural Characterization and Pharmacological Evaluation, in Proceedings of The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics, 1 November–30 November 2025, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Development of Kojic Acid–3-Hydroxyindolin-2-one Conjugates: Structural Characterization and Pharmacological Evaluation

Karthikeyan Chandrabose 1,2
1. Cancept Therapeutics Lab, Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, 484887 M.P., India, India
2. College of Pharmacy, University of Arkansas for Medical Sciences. 4301W. Markham St., Little Rock, AR 72205, India
Abstract

Kojic acid (KA), a natural compound with notable biological properties, is a versatile scaffold (5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one) for developing novel therapeutic agents. This study aimed to synthesize KA-based derivatives and evaluate their multifunctionality as anti-tyrosinase, anticancer, antioxidant, and anti-malarial agents. Exploring KA derivatives holds promise for advancing in skin brightening, malaria, and cancer therapeutics, and managing oxidative stress, addressing the demanding need for multifunctional compounds in modern medicine. KA derivative (DRC-01) was synthesized through one-pot aldol condensation chemical reactions and structurally confirmed using advanced spectroscopic techniques, including FTIR, NMR, and mass spectrometry. The anti-tyrosinase activity on Mushroom Tyrosinase protein from RCSB PDB (PDB: 2Y9X) and anticancer potential were evaluated in vitro using the MTT assay against human cancer cell lines: HCT-116 (colon cancer), PANC-1 (pancreatic cancer), MDA-MB-231 (triple-negative breast cancer), and MCF-7 (hormone-responsive breast cancer). Antioxidant activity was assessed using the DPPH assay to determine radical scavenging properties, and the Antimalarial activity was performed by SYBR GREEN assay in Plasmodium falciparum 3D7. DRC-01 showed binding energy -7.4kcal/mol compared to standard KA -5.8kcal/mol and dose-dependent cytotoxicity, demonstrating anticancer activity at higher concentrations (>50 µM) across all tested cell lines. Additionally, DRC-01 displayed moderate radical scavenging activity in the antioxidant assay, and Antimalarial potential was at IC50 = 54.94±3.11µg/mL. These findings highlight that DRC-01 could be a candidate for therapeutic applications with its cosmeceutical properties. Further structural optimization is acceptable to enhance their potency and selectivity, reinforcing their value in the fight against cancer, malaria, and oxidative stress-related disorders.

Keywords
Kojic acid
Isatin
anti-cancer
Antioxidant
MTT assay
antimalaria
anti-tyrosinase
Poster
[ECMC-P 2025] sciforum-149955 Dau Ram.pdf
Pharmacokinetics and inhibitory activities of UPLC-detected compounds of Voacanga africana roots on acetylcholinesterase and monoamine oxidase B: Potential drug candidates for neurological disorders
Development and Characterization of a Stable Capsule Formulation containing Lyophilized (Freeze Drying) Monoclonal Antibody (mAb) for Oral Administration